ERBB2 and neoplasm: Finally, low CD8+ stromal TILs in primary tumour predict inferior response to lapatinib vs. trastuzumab in the metastatic setting, according to TIL assessment from the phase III RCT MA.31, which randomized metastatic HER2+ patients to receive a taxane plus either trastuzumab or lapatinib [55].